Eruptive Melanocytic Nevi Secondary to Chemotherapy in a Pediatric Patient a Case Report

Main Article Content

Chloe Haverkamp
Rafael Mojia-Ruiz
Michael Lavery

Keywords

Chemotherapy, Eruptive Melanocytic Nevi, Pediatric Dermatology, Acute Lymphoblastic Leukemia

Abstract

Introduction: Eruptive Melanocytic Nevi (EMN) is an uncommon skin manifestation of either skin trauma, immunosuppression due to internal disease, or pharmacotherapy. As the use of biological therapy increases and new chemotherapy regimens form, there is potential for an increase in the incidence of EMN.


Case Report: In the case described in this study, a 9-year-old boy presents with EMN, which formed during his chemotherapy treatment for acute lymphoblastic leukemia (ALL). He completed treatment with a relatively new chemotherapy regimen, which was associated with EMN in one prior study. Since the completion of treatment in 2020, the nevi have remained stable and have not developed any gross or dermoscopic features concerning for malignancy.


Discussion: There has not been enough wide-scale research conducted on EMN secondary to chemotherapy to confidently say if these nevi are at a higher risk of malignancy than typical melanocytic nevi. For this reason, current recommendations are to monitor patients with EMN for malignancy closely throughout their lifetime. This case means to increase awareness and understanding of this rare chemotherapy reaction, and potentially contribute to future decision making regarding the management of EMN.

References

1. Burian, E.A., Jemec, G.B.E. Eruptive Melanocytic Nevi: A Review. Am J Clin Dermatol 20, 669–682 (2019). https://doi.org/10.1007/s40257-019-00444-8

2. Perry BM, Nguyen A, Desmond BL, Blattner CM, Thomas RS, Young RJ. Eruptive Nevi associated with medications (enams). Journal of the American Academy of Dermatology. 2016;75(5):1045-1052. doi:10.1016/j.jaad.2016.04.064

3. Vena GA, Fargnoli MC, Cassano N, Argenziano G. Drug-induced eruptive melanocytic Nevi. Expert Opinion on Drug Metabolism & Toxicology. 2016;13(3):293-300. doi:10.1080/17425255.2017.1247155

4. Koseoglu G, Akay BN, Kucuksahin O, Erdem C. Dermoscopic changes in melanocytic nevi in patients receiving immunosuppressive and biologic treatments: Results of a prospective case-control study. Journal of the American Academy of Dermatology. 2015;73(4):623-629. doi:10.1016/j.jaad.2015.07.013

5. Stewart CJ, Hawkins CN. Eruptive Acral Nevi Secondary to Treatment With Chemotherapy. JAMA Dermatol. 2023;159(7):782. doi:10.1001/jamadermatol.2022.6543

6. Uksal U, Ozturk P, Colgecen E, Taslidere N, Patiroglu T, Ozdemir MA, Torun YA, Borlu M. Dermatological Findings in Turkish Paediatric Haematology-Oncology Patients. Eurasian J Med. 2016 Jun;48(2):107-11. doi: 10.5152/eurasianjmed.2015.86. PMID: 27551173; PMCID: PMC4970547.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.